AFP DEPARTMENT COLLECTION
This department includes information about new drugs from the perspective of the five attributes to be considered when weighing the advantages of one drug over another: Safety, Tolerability, Effectiveness, Price, and Simplicity.
Jul 15, 2019 Issue
Semaglutide (Ozempic) for Type 2 Diabetes Mellitus
Semaglutide can be added to existing treatment to improve glycemic control and induce weight loss. It may also protect against cardiovascular outcomes in patients with type 2 diabetes and established cardiovascular disease.
Jun 15, 2019 Issue
Erenumab (Aimovig) for Migraine Prophylaxis in Adults
Erenumab is a safe option for migraine prophylaxis in adults. However, it is expensive and should be reserved for patients who have experienced intolerable adverse effects while taking oral migraine prophylaxis medication or who have poor adherence to daily preventive treatment.
May 15, 2019 Issue
Glycopyrrolate (Lonhala Magnair) for Treatment of Chronic Obstructive Pulmonary Disease
Glycopyrrolate is a safe alternative to long-acting muscarinic antagonists delivered by metered-dose inhaler for patients with moderate to severe COPD.
Mar 15, 2019 Issue
Lofexidine (Lucemyra) for Treatment of Opioid Withdrawal Symptoms
Lofexidine has been shown to be as effective as clonidine at controlling some of the symptoms of withdrawal from opioid use. It may have a small additional benefit for maintaining abstinence in patients switched to buprenorphine or methadone for long-term maintenance.
Feb 15, 2019 Issue
Abaloparatide (Tymlos) for Osteoporosis
Abaloparatide is a safe and effective medication used to reduce the likelihood of vertebral and nonvertebral fractures in women at high risk. However, it is expensive and requires daily injections. It has not been evaluated for its effect on decreasing hip fractures.
Jan 15, 2019 Issue
Prasterone (Intrarosa) for Dyspareunia
Prasterone is similarly effective to nonprescription options for treating vaginal dryness and itching associated with menopause and may offer a small benefit in the treatment of dyspareunia.
Nov 15, 2018 Issue
Glecaprevir/Pibrentasvir (Mavyret) for the Treatment of Chronic Hepatitis C
Glecaprevir/pibrentasvir is an effective treatment for any of six genotypes of HCV infection and has few adverse effects. It can be used to treat more genotypes over a shorter duration (eight weeks for patients without cirrhosis) and is substantially less expensive than other available treatments.
Oct 15, 2018 Issue
Recombinant Zoster Vaccine (Shingrix) for the Prevention of Shingles
Recombinant zoster vaccine is a relatively new shingles vaccine that has been shown to have greater effectiveness and protection than the existing live vaccine. Local and systemic adverse effects may occur after administration, but have been shown to resolve within one to three days.
Sep 15, 2018 Issue
Crisaborole (Eucrisa) for Mild to Moderate Atopic Dermatitis
Crisaborole has been shown to be effective in about one-third of patients who use it, but it is much more expensive than other available products. Although crisaborole is a safe option for patients in whom topical corticosteroids are considered risky (e.g., children at least two years of age), it should not be routinely considered until long-term effectiveness and safety data become available.
Aug 15, 2018 Issue
Delafloxacin (Baxdela) for Skin Infections
Delafloxacin is a new fluoroquinolone antibiotic available in intravenous and oral formulations for the treatment of serious skin and skin structure infections in patients requiring initial intravenous therapy. It is effective for infections caused by MRSA or P. aeruginosa, in addition to other common causative pathogens, but has not been shown to be more effective than existing antibiotic regimens.